Metoxia

A European Collaborative Project within Health Research, funded with the support of the Seventh Framework Programme (FP7) and coordinated by the Department of Physics, University of Oslo, Norway.

METOXIA project progress update Apr 10, 2013 03:20 PM

A summary of the METOXIA project's progress is now available on our website under About METOXIA - Project progress . The summery is the official publishable summary as provided in our 2nd scientific report covering the period up untill 31.01.2011.
METOXIA article in the Public Service Review Apr 10, 2013 03:20 PM

New methods to detect cancer micro-environmental parameters are developed alongside new therapeutic principles in the form of chemicals as possible new chemotherapeutic drugs and new methods to improve radiotherapy
METOXIA project meeting in Bratislava Jun 6, 2012 11:52 AM

METOXIA General Assembly meeting starts Tuesday morning 12th June at 09:00, and ends 16:30 on Wednesday afternoon.

Practical information, as sent out by e-mail, and latest programme is now available on our member's area (members only - for access contact hilde.hvistendahl@mn.uio.no)

Looking forward to seeing you in Bratislava!
METOXIA's annual reporting for partners coming up Jan 18, 2012 04:19 PM

The periodic report for the 3 period covers activities during 01.02.2011-31.1.2012.

The reporting deadlines are in February.

Please see the information on reporting as sent you by e-mail on 17. and 18. January. The same information is also available on our website, see: members area/periodic reports/3rd report 2011/12.

If you need access to the members area, please e-mail hilde.hvistendahl@mn.uio.no.It is easily granted now with our new system.
New login for members area Sep 23, 2011 11:08 AM

METOXIA partners have been invited to the internal member site of METOXIA and asked to create a "WebID". If you have received such an invitation, please accept within a week.

Contact

METOXIA

Solid cancers generally contain areas with abnormally low levels of oxygen. Such areas are denoted hypoxic. It has long been known that cancer cells in such hypoxic micro-environments are resistant to treatment.

Recent research has furthermore shown that hypoxia in tumors is one of the major drivers of metastatic spread of cancer, the major cause of death by the disease. Thus, hypoxia is responsible for a double effect of reducing the potential of a successful treatment of the cancer patient: Resistance to treatment and ability to spread. At the same time the very low level of oxygen found in solid tumors are specific to cancer.

Therefore, if one could develop methods that specifically located and inactivated cells in hypoxic areas one might obtain a cancer-specific effect, selective for the most harmful of the cancer cells. This development is the core task of the METOXIA project.